北京大学学报(医学版) ›› 2016, Vol. 48 ›› Issue (4): 667-671. doi: 10.3969/j.issn.1671-167X.2016.04.020

• 论著 • 上一篇    下一篇

趋化因子配体19在类风湿关节炎患者血清中的表达及临床意义

石连杰1,李建红2,胡凡磊1,李敏3,张杰4,李江涛4,栗占国1△   

  1. (1. 北京大学人民医院风湿免疫科, 北京100044; 2. 四川大学华西医院核医学科, 成都610041; 3. 四川省骨科医院风湿科, 成都610041; 4. 宜宾市第一医院风湿科, 四川宜宾644000)
  • 出版日期:2016-08-18 发布日期:2016-08-18
  • 通讯作者: 栗占国 E-mail:zgli99@aliyun.com

Clinical significance of serum C-C chemokine ligand 19 levels in patients with rheumatoid arthritis

SHI Lian-jie1, LI Jian-hong2, HU Fan-lei1, LI Min3, ZHANG Jie4, LI Jiang-tao4, LI Zhan-guo1△   

  1. (1. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing 100044, China; 2. Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China; 3. Department of Rheumatology, Sichuan Orthopedic Hospital, Chengdu 610041, China; 4. Department of Rheumatology, The First People’s Hospital of Yibin, Yibin 644000, Sichuan, China)
  • Online:2016-08-18 Published:2016-08-18
  • Contact: LI Zhan-guo E-mail:zgli99@aliyun.com

摘要:

目的:探讨趋化因子配体19(C-C chemokine ligand 19,CCL19)在类风湿关节炎(rheumatoid arthritis,RA)患者血清中的表达水平及临床意义。方法:采用酶联免疫吸附测定检测RA患者和健康对照血清CCL19的表达水平,收集患者临床及实验室资料,利用流式细胞术检测患者外周血B细胞及记忆B细胞亚群的比例。对比不同临床特征的RA患者血清CCL19表达差异,分析血清CCL19水平与临床及实验室指标、B细胞及记忆B细胞亚群间的相关性。数据分析采用独立样本t检验、配对t检验、Pearson和Spearman相关分析。结果:RA患者血清中高表达CCL19(P<0.001),治疗后的RA患者CCL19表达显著降低(P<0.001)。CCL19与红细胞沉降率(erythrocyte sedimentation rate,ESR)、C反应蛋白(C-reactive protein,CRP)、28个关节的疾病活动度评分(disease activity score in 28 joints,DAS28)无相关性(P>0.05),但与类风湿因子(rheumatoid factor,RF)、抗环瓜氨酸多肽(cyclic citrullinated peptide,CCP)抗体水平显著相关(r=0.42,P=0.002;r=0.33,P=0.013);CCL19水平在抗CCP抗体阳性组显著高于抗CCP抗体阴性组,RF阳性组显著高于RF阴性组,高、低疾病活动组间以及早期和非早期RA组间差异均无统计学意义;CCL19与外周血CD19+、CD27+、D27-、CD27+IgD+、CD27+IgD-、CD27-IgD+、CD27-IgD- B细胞的比例均未见显著相关性(P>0.05)。相较于健康对照,RA患者外周血CD27+IgD+、CD27+IgD-、CD27+ B细胞比例均显著减少。结论:血清CCL19水平可以反映RA患者的免疫活动状态,可预判RA患者B细胞抗体分泌的功能状态,从而可能指导RA临床治疗策略的选择。

关键词: 关节炎, 类风湿, 趋化因子CCL19, 类风湿因子, 抗体, B淋巴细胞

Abstract:

Objective:To investigate the serum level of C-C chemokine ligand 19 (CCL19) and its clinical significance in rheumatoid arthritis. Methods: The serum CCL19 levels in both rheumatoid arthritis (RA) patients and health controls were detected by ELISA. The proportion of peripheral blood B cells and memory B cell subsets were also detected in some patients. Then the clinical and laboratory data of the patients were collected. The CCL19 levels in patients with different clinical features were analyzed. And the correlation between the clinical data, laboratory parameters, B cell subsets proportion and serum CCL19 levels were also analyzed. Independent samples t test, paired t test, Pearson and Spearman correlation were used for statistical analysis. Results: The levels of CCL19 was higher in the RA patients than the health controls (P<0.05). The serum CCL19 levels were decreased in the RA patients who accep-ted disease-modifying anti-rheumatic drugs (DMARDs) treatment for 6 months (P<0.001). Serum CCL19 levels were correlated with the titers of both rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibody (r=0.42, P=0.002; r=0.33, P=0.013), but not with erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and disease activity score in 28 joints (DAS28) (P>0.05). The levels of CCL19 were higher in the serum positive (RF and anti-CCP antibody) patients, but there were no differences between low and high disease activity RA, as well as early and non-early RA. There was no correlation between the serum CCL19 levels and the proportion of B cells as well as memory B subsets. All the proportion of peripheral blood CD27+ memory B cell subsets in RA was lower than the healthy controls, including CD27+IgD+, CD27+IgD- and CD27+ B cells. Conclusion: The increased serum CCL19 levels in RA patients are associated with the activity of B cells, so CCL19 might predict whether the RA type is a B cell mediated RA, and specify the treatment directions for the rheumatologist.

Key words: Arthritis, rheumatoid, Chemokine CCL19, Rheumatoid factor, Antibodies, B-lymphocytes

中图分类号: 

  • R593.22
[1] 杨玉淑, 齐晅, 丁萌, 王炜, 郭惠芳, 高丽霞. 抗唾液腺蛋白1抗体联合抗腮腺分泌蛋白抗体对干燥综合征的诊断价值[J]. 北京大学学报(医学版), 2024, 56(5): 845-852.
[2] 刘东武, 陈杰, 高明利, 于静. 类风湿关节炎伴发淋巴结Castleman样病理改变1例[J]. 北京大学学报(医学版), 2024, 56(5): 928-931.
[3] 李正芳,罗采南,武丽君,吴雪,孟新艳,陈晓梅,石亚妹,钟岩. 抗氨基甲酰化蛋白抗体在诊断类风湿关节炎中的应用价值[J]. 北京大学学报(医学版), 2024, 56(4): 729-734.
[4] 黄会娜,赵静,赵祥格,白自然,李霞,王冠. 乳酸对类风湿关节炎患者外周血CD4+T细胞亚群的调控作用[J]. 北京大学学报(医学版), 2024, 56(3): 519-525.
[5] 汤晓菲,李永红,丁秋玲,孙卓,张阳,王育梅,田美伊,刘坚. 类风湿关节炎患者下肢深静脉血栓发病率及危险因素[J]. 北京大学学报(医学版), 2024, 56(2): 279-283.
[6] 赖展鸿,李嘉辰,贠泽霖,张永刚,张昊,邢晓燕,邵苗,金月波,王乃迪,李依敏,李玉慧,栗占国. 特发性炎性肌病完全临床应答相关因素的单中心真实世界研究[J]. 北京大学学报(医学版), 2024, 56(2): 284-292.
[7] 李红光,韩玮华,吴训,冯继玲,李刚,孟娟红. 关节腔冲洗联合液态浓缩生长因子注射治疗单侧颞下颌关节骨关节炎的初步研究[J]. 北京大学学报(医学版), 2024, 56(2): 338-344.
[8] 韩艺钧,李常虹,陈秀英,赵金霞. 抗SSB抗体阳性和阴性的原发性干燥综合征患者临床及免疫学特征的比较[J]. 北京大学学报(医学版), 2023, 55(6): 1000-1006.
[9] 邹雪,白小娟,张丽卿. 艾拉莫德联合托法替布治疗难治性中重度类风湿关节炎的疗效[J]. 北京大学学报(医学版), 2023, 55(6): 1013-1021.
[10] 罗靓,李云,王红彦,相晓红,赵静,孙峰,张晓盈,贾汝琳,李春. 抗内皮细胞抗体检测在早期流产中的预测价值[J]. 北京大学学报(医学版), 2023, 55(6): 1039-1044.
[11] 李宇菲,闫亚妮,靳家扬,李春,裴秋艳. 合并胎儿心脏病变的抗SSA抗体阳性孕妇的临床及实验室特征[J]. 北京大学学报(医学版), 2023, 55(6): 1053-1057.
[12] 姚中强,李常虹,李欣艺,郭苇,翟佳羽,刘蕊,魏慧,穆荣. 抗磷脂酰丝氨酸/凝血酶原抗体与不明原因复发性流产的相关性分析[J]. 北京大学学报(医学版), 2023, 55(6): 1058-1061.
[13] 孟彦宏,陈怡帆,周培茹. CENP-B抗体阳性的原发性干燥综合征患者的临床和免疫学特征[J]. 北京大学学报(医学版), 2023, 55(6): 1088-1096.
[14] 卢情怡,艾尼扎提·哈斯木,李宇菲,李春. 抗神经酰胺抗体在抗磷脂综合征中的分布及临床意义[J]. 北京大学学报(医学版), 2023, 55(6): 1139-1143.
[15] 李嘉辰,赖展鸿,邵苗,金月波,高小娟,张科,侯儆,张燕英,栗占国,李玉慧. 抗Jo-1抗体在特发性炎性肌病临床分层及疾病谱中的意义[J]. 北京大学学报(医学版), 2023, 55(6): 958-965.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!